New hope for lung cancer: experimental drug ANS02 enters human trials

NCT ID NCT07538804

Recruiting now Disease control Sponsor: Avistone Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study tests a new drug called ANS02 in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The trial has two phases: first, finding a safe dose, then checking if the drug shrinks tumors. About 294 participants will take ANS02 alone, and researchers will monitor side effects and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ANS02 (a drug being tested for advanced lung cancer)
What this could lead to: If successful, this could point toward a new treatment option for people with EGFR-mutated non-small cell lung cancer that hasn't responded to other therapies.
What could go wrong: This is an early first-in-human trial, so safety and effectiveness are not yet known. Many experimental drugs fail in early testing, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Research Site
RECRUITING

Fairfax, Virginia, 22031, United States
Research Site
NOT_YET_RECRUITING

Guangzhou, Guangdong, China
Research Site
RECRUITING

Harbin, Heilongjiang, China
Research Site
NOT_YET_RECRUITING

Zhengzhou, Henan, China
Study Site
NOT_YET_RECRUITING

Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.